Since MSTN levels are increased in muscle fibers suffering from s-IBM, and considering the NF-κB binding sites are found in the MSTN promoter region [36, 92], the authors hypothesised that interfering with this mechanism might provide a therapeutic possibility for s-IBM as well as other muscle atrophy conditions. This evidence concerns the gene NFKB1 and inclusion body myositis.